Related Experiment Videos
Kunjin virus replicon vectors for human immunodeficiency virus vaccine development
Tracey J Harvey1, Itaru Anraku, Richard Linedale
1Sir Albert Sakzewski Virus Research Centre, Royal Children's Hospital, University of Queensland, Brisbane, Queensland, 4029 Australia.
Journal of Virology
|June 28, 2003
Summary
Kunjin (KUN) replicon RNA vaccine vectors effectively induced Gag-specific antibodies and potent CD8+ T-cell responses against HIV-1 Gag antigen in mice. These KUN replicon virus-like particle (VLP) vaccinations offered long-lasting protection.
Area of Science:
- Virology
- Immunology
- Vaccinology
Background:
- Previous studies demonstrated Kunjin (KUN) replicon RNA vaccine vectors' ability to induce CD8+ T-cell responses.
- The KUN replicon system utilizes Australian flavivirus RNA for vaccine vector development.
Purpose of the Study:
- To evaluate KUN replicon vectors encoding HIV-1 Gag antigen for their capacity to induce Gag-specific immune responses.
- To assess the efficacy of KUN replicon-based vaccines in eliciting both antibody and CD8+ T-cell mediated protection against HIV-1.
Main Methods:
- BALB/c mice were immunized with KUN replicons encoding HIV-1 Gag antigen, delivered via virus-like particles (VLPs), plasmid DNA, or naked RNA.
- Humoral and cellular immune responses, including antibody titers and Gag-specific CD8+ T-cell induction, were measured.
- Vaccine efficacy was assessed through protection against challenge with recombinant vaccinia virus expressing the gag gene (rVVgag).
- The durability of immune responses was evaluated over 6 to 10 months post-immunization.
Main Results:
- Two immunizations with KUNgag VLPs induced high titers (> or =1:10,000) of anti-Gag antibodies.
- KUNgag replicons, regardless of delivery method (DNA, RNA, VLPs), induced potent Gag-specific CD8+ T-cell responses.
- A single KUNgag VLP immunization generated 4.5-fold more CD8+ T cells compared to rVVgag.
- Two KUNgag VLP immunizations provided significant protection against rVVgag challenge.
- Vaccinations induced long-lasting immune responses, with CD8+ T cells maintaining functionality for 6-10 months.
Conclusions:
- KUN replicon vectors encoding HIV-1 Gag antigen are effective in inducing robust Gag-specific antibody and CD8+ T-cell responses.
- KUN replicon VLPs demonstrate significant potential as a vaccine platform for human immunodeficiency virus (HIV) vaccine design.
- The long-lasting nature of the induced immune responses highlights the therapeutic promise of KUN replicon VLP vaccinations.